Eiko Lifescience

  • Market Cap: Micro Cap
  • Industry: Specialty Chemicals
  • ISIN: INE666Q01016
  • NSEID:
  • BSEID: 540204
INR
49.74
0.72 (1.47%)
BSENSE

Mar 30

BSE+NSE Vol: 10.43 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
{
  "main_header": {
    "sid": 1002696,
    "name": "Eiko Lifescience",
    "stock_name": "Eiko Lifescience",
    "full_name": "Eiko Lifesciences Ltd",
    "name_url": "stocks-analysis/eiko-lifescience",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "49.74",
    "chg": 0.72,
    "chgp": "1.47%",
    "dir": 1,
    "prev_price": "49.02",
    "mcapval": "70.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 540204,
    "symbol": "",
    "ind_name": "Specialty Chemicals",
    "ind_code": 5,
    "indexname": "India SENSEX",
    "isin": "INE666Q01016",
    "curr_date": "Mar 30",
    "curr_time": "",
    "bse_nse_vol": "10.43 k",
    "exc_status": "Active",
    "traded_date": "Mar 30, 2026",
    "traded_date_str": "2026 03 30",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/eiko-lifescience-1002696-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Eiko Lifesciences Ltd Falls to 52-Week Low of Rs 45.9 as Sell-Off Deepens",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/eiko-lifesciences-ltd-stock-hits-52-week-low-at-rs459-3925321",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/EikoLifescience_priceRelatedfactors_3925321.png",
        "date": "2026-03-30 14:27:25",
        "description": "A 30.3% decline from its 52-week high of Rs 65.9 has dragged Eiko Lifesciences Ltd to a fresh 52-week low of Rs 45.9 on 30 Mar 2026, marking a notable downturn despite recent positive earnings trends."
      },
      {
        "title": "Eiko Lifesciences Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/eiko-lifesciences-ltd-is-rated-sell-3923881",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/EikoLifescience_mojoScore_3923881.png",
        "date": "2026-03-30 10:10:02",
        "description": "Eiko Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 March 2026, providing investors with an up-to-date perspective on the company’s performance and outlook."
      },
      {
        "title": "Eiko Lifesciences Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/eiko-lifesciences-ltd-is-rated-sell-3893350",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/EikoLifescience_mojoScore_3893350.png",
        "date": "2026-03-16 10:10:02",
        "description": "Eiko Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 March 2026, providing investors with the most up-to-date insight into the company's performance and outlook."
      },
      {
        "title": "Eiko Lifesciences Ltd is Rated Sell by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/eiko-lifesciences-ltd-is-rated-sell-by-marketsmojo-3869040",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/EikoLifescience_mojoScore_3869040.png",
        "date": "2026-03-04 10:10:02",
        "description": "Eiko Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook."
      },
      {
        "title": "Eiko Lifesciences Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/eiko-lifesciences-ltd-is-rated-sell-3842357",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/EikoLifescience_mojoScore_3842357.png",
        "date": "2026-02-16 10:10:04",
        "description": "Eiko Lifesciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 20 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 16 February 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Eiko Lifesciences Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/eiko-lifesciences-ltd-is-rated-sell-3817799",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/EikoLifescience_mojoScore_3817799.png",
        "date": "2026-02-03 10:14:03",
        "description": "Eiko Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 January 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 03 February 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Eiko Lifesciences Ltd Valuation Shifts Signal Renewed Price Attractiveness",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/eiko-lifesciences-ltd-valuation-shifts-signal-renewed-price-attractiveness-3813786",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/EikoLifescience_valuationdot_3813786.png",
        "date": "2026-02-01 08:06:00",
        "description": "Eiko Lifesciences Ltd, a player in the Specialty Chemicals sector, has witnessed a notable improvement in its valuation attractiveness, shifting from very attractive to attractive. Despite a mixed performance against benchmark indices, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a more compelling entry point for investors, even as its overall market sentiment remains cautious with a recent downgrade to a Sell rating."
      },
      {
        "title": "Why is Eiko Lifesciences Ltd falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-eiko-lifesciences-ltd-fallingrising-3812260",
        "imagepath": "",
        "date": "2026-01-31 00:55:24",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Performance and Market Context</strong></p>\n<p>Eiko Lifesciences has demonstrated notable resilience and strength in the short term, outperforming the broader market and its sector peers. Over the past week, the stock has delivered a remarkable 10.39% gain, substantially outpacing the Sensex’s modest 0.90% rise during the same period. This outperformance is particularly striking given the Sensex’s negative returns over the past month and year-to-date, which stand at -2.84% and -3.46% respectively. While the stock’s one-year return of 2.45% trails the Sensex’s 7.18%, its recent momentum signals renewed investor confidence.</p>\n<p><strong>Technical Indicators and Trading Activity</strong></p>\n<p>The stock’s technical positioning is robust, trading above all key moving averages inc..."
      },
      {
        "title": "Are Eiko Lifesciences Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-eiko-lifesciences-ltd-latest-results-good-or-bad-3810120",
        "imagepath": "",
        "date": "2026-01-29 19:24:35",
        "description": "Eiko Lifesciences Ltd's latest financial results for Q2 FY26 reflect a significant year-on-year growth in both net sales and net profit, indicating a robust operational performance. The company reported net sales of ₹11.67 crores, which represents a 43.01% increase compared to ₹8.16 crores in the same quarter last year. This growth is complemented by a substantial rise in net profit, which reached ₹1.08 crores, marking a remarkable 285.71% increase year-on-year. Additionally, the operating margin improved significantly to 15.17%, up from 5.15% in the previous year, showcasing enhanced operational efficiency.\n\nHowever, despite these positive metrics, the company faces challenges regarding its long-term financial health. The average return on equity (ROE) stands at a low 2.71%, raising concerns about capital efficiency and shareholder value creation. This weak ROE is notably below industry standards, suggesti..."
      }
    ],
    "total": 481,
    "sid": "1002696",
    "stock_news_url": "https://www.marketsmojo.com/news/eiko-lifesciences-1002696"
  },
  "announcements": [
    {
      "caption": "Closure of Trading Window",
      "datetime": "25-Mar-2026",
      "details": "Pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015 as amended and as per Companys Code of Conduct for Regulating Monitoring and Reporting of Trading by Insiders (Code) the trading window for dealing in the securities of the Company shall remain closed for designated persons and their immediate relatives from Wednesday 01st April 2026 till 48 hours after the date of Board Meeting wherein inter-alia the approval of Audited Standalone and Consolidated Financial Results for the quarter and year ended 31st March 2026 would be considered by the Board.",
      "source": "BSE"
    },
    {
      "caption": "Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011",
      "datetime": "26-Feb-2026",
      "details": "The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Bhavesh Dhirajlal Tanna",
      "source": "BSE"
    },
    {
      "caption": "Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011",
      "datetime": "26-Feb-2026",
      "details": "The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Lenus Finvest Pvt Ltd",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Eiko Lifesciences Ltd has declared <strong>2%</strong> dividend, ex-date: 20 Sep 17",
          "dt": "2017-09-20",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "",
      "data": [
        {
          "txt": "Eiko Lifesciences Ltd has announced <strong>2:3</strong> rights issue, ex-date: 07 Jul 23",
          "dt": "2023-07-07",
          "middle_text": "Rights Issue"
        }
      ]
    }
  ]
}
stock newsNews and Views

Why is Eiko Lifesciences Ltd falling/rising?

2026-01-31 00:55:24

Recent Price Performance and Market Context

Eiko Lifesciences has demonstrated notable resilience and strength in the short term, outperforming the broader market and its sector peers. Over the past week, the stock has delivered a remarkable 10.39% gain, substantially outpacing the Sensex’s modest 0.90% rise during the same period. This outperformance is particularly striking given the Sensex’s negative returns over the past month and year-to-date, which stand at -2.84% and -3.46% respectively. While the stock’s one-year return of 2.45% trails the Sensex’s 7.18%, its recent momentum signals renewed investor confidence.

Technical Indicators and Trading Activity

The stock’s technical positioning is robust, trading above all key moving averages inc...

Read full news article
stock-recommendationAnnouncement

Closure of Trading Window

25-Mar-2026 | Source : BSE

Pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015 as amended and as per Companys Code of Conduct for Regulating Monitoring and Reporting of Trading by Insiders (Code) the trading window for dealing in the securities of the Company shall remain closed for designated persons and their immediate relatives from Wednesday 01st April 2026 till 48 hours after the date of Board Meeting wherein inter-alia the approval of Audited Standalone and Consolidated Financial Results for the quarter and year ended 31st March 2026 would be considered by the Board.

Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011

26-Feb-2026 | Source : BSE

The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Bhavesh Dhirajlal Tanna

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011

26-Feb-2026 | Source : BSE

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Lenus Finvest Pvt Ltd

stock-recommendationCorporate Actions
Corporate Actions
info
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

Eiko Lifesciences Ltd has declared 2% dividend, ex-date: 20 Sep 17

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

Eiko Lifesciences Ltd has announced 2:3 rights issue, ex-date: 07 Jul 23